Prospective Histopathologic Comparison Between [ 18 F]PSMA-1007 PET/CT and [ 18 F]Fluciclovine PET/CT of Intraprostatic Tumor Detection: The TRACER Study
Journal of Nuclear Medicine · 2026
DOI: 10.2967/jnumed.125.270650 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Robert J Hoekstra und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Catharina Hospital, Eindhoven, The Netherlands; robert.hoekstra@catharinaziekenhuis.nl. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Cyclobutanes, Carboxylic Acids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Both [18F]PSMA-1007 PET/CT and [18F]fluciclovine PET/CT scans are commonly used for prostate cancer (PCa) staging. To the best of our knowledge, no head-to-head comparison of these 2 scans for detection of intraprostatic clinically significant PCa (csPCa) has been published.
Methods
A multicenter prospective histopathologic validation study was conducted from October 2020 to February 2023. Patients with newly diagnosed biopsy-proven intermediate- or high-risk PCa scheduled for robot-assisted radical prostatectomy (RARP) were consecutively included. Before RARP, patients underwent both [18F]PSMA-1007 PET/CT as well as [18F]fluciclovine PET/CT. The diagnostic accuracy of [18F]PSMA-1007 PET/CT and [18F]fluciclovine PET/CT for intraprostatic PCa detection and localization was established by histopathologic examination of the prostate specimen as reference. Sensitivity, specificity, positive predictive value, and negative predictive value were compared. Results were based on per-lesion analysis and per-segment analysis. The focus was set on csPCa, defined as the International Society of Urological Pathology grade group 2 or higher.
Results
In total, 77 patients were included of whom 57 underwent both PET/CT scans before RARP. Histopathology of the prostate specimen found a total of 88 lesions, of which 68 (77.3%) were qualified as csPCa. Using [18F]PSMA-1007 PET/CT, lesion-based sensitivity for csPCa was 86.8% (95% CI, 75.9%-93.4%), and with [18F]fluciclovine PET/CT, it was 73.5% (95% CI, 61.2%-83.2%). Sensitivity for segment-based csPCa localization was 46.6% (95% CI, 42.4%-50.8%) for [18F]PSMA-1007 PET/CT and 37.3% (95% CI, 33.3%-41.5%) for [18F]fluciclovine PET/CT. Whereas [18F]PSMA-1007 PET/CT has a significantly higher accuracy in the detection and localization of csPCa, [18F]fluciclovine PET/CT visualized all 5 non-[18F]PSMA-1007-avid index tumors.
Conclusion
Compared with [18F]fluciclovine PET/CT, [18F]PSMA-1007 PET/CT demonstrated higher sensitivity for csPCa detection. However, in non-[18F]PSMA-1007-avid tumors, the [18F]fluciclovine PET/CT can visualize csPCa and has therefore a potential role in the diagnostic work-up and the clinical decision-making process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Catharina Hospital, Eindhoven, The Netherlands; robert.hoekstra@catharinaziekenhuis.nl.
- Prosper Prostate Cancer Clinics, Nijmegen, The Netherlands.
- Department of Urology, Catharina Hospital, Eindhoven, The Netherlands.
- Department of Nuclear Medicine, Catharina Hospital, Eindhoven, The Netherlands.
- Department of Radiology, Catharina Hospital, Eindhoven, The Netherlands.
- Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
Zitieren
APA
Hoekstra, R. J., Peeters, L., Beulens, A., Roef, M. J., Brouwer, C., Nederend, J., Küsters-Vandevelde, H. V. N., Beerlage, H. P., Baas, D. J. H., Somford, D. M., Sedelaar, M., van Basten, J. A., & Vrijhof, H. J. E. J. (2026). Prospective Histopathologic Comparison Between [ 18 F]PSMA-1007 PET/CT and [ 18 F]Fluciclovine PET/CT of Intraprostatic Tumor Detection: The TRACER Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270650
Vancouver
Hoekstra RJ, Peeters L, Beulens A, Roef MJ, Brouwer C, Nederend J, et al. Prospective Histopathologic Comparison Between [ 18 F]PSMA-1007 PET/CT and [ 18 F]Fluciclovine PET/CT of Intraprostatic Tumor Detection: The TRACER Study. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.270650
BibTeX
@article{Hoekstra2026,
author = {Hoekstra, Robert J and Peeters, Lisa and Beulens, Alexander and Roef, Mark J and Brouwer, Christel and Nederend, Joost and Küsters-Vandevelde, Heidi V N and Beerlage, Harrie P and Baas, Diederik J H and Somford, Diederik M and Sedelaar, Michiel and van Basten, Jean-Paul A and Vrijhof, Hendricus J E J},
title = {Prospective Histopathologic Comparison Between [ 18 F]PSMA-1007 PET/CT and [ 18 F]Fluciclovine PET/CT of Intraprostatic Tumor Detection: The TRACER Study},
journal = {Journal of Nuclear Medicine},
year = {2026},
doi = {10.2967/jnumed.125.270650}
}
EUVIMED